德康醫療 DXCM 深 滬
等待開盤 06-25 09:30:00 美东时间
69.75
+0.830
+1.20%
華盛通- 最 高71.085
- 今 開69.00
- 成交量 383.20万股
- 最 低 68.92
- 昨 收 68.92
- 總市值 269.15亿
- 52周最高 89.98
- 市盈率 靜 33.38
- 換手率 0.99%
- 52周最低 54.11
- 委 比 7.57%
- 總股本 3.86亿
- 歷史最高 164.863
- 量 比 0.68
- 振 幅 3.14%
- 歷史最低 1.6875
- 每 手 1
- 風險率 7.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多德康医疗将推出全新改版Stelo应用并实施全球扩张计划
德康医疗（DXCM）宣布将于7月起在美国上线全面更新的Stelo应用，适配苹果与安卓设备，为用户提供更易操作的血糖洞察服务。同时公司公布Stelo平台国际扩张计...
06-24 22:37
美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
Dexcom跌4.69% 看跌势头加剧
核心事件：德康医疗（DXCM）最新交易日收跌4.69%，报69.07美元，自6月15日75.70美元高点以来持续走弱，技术面整体呈现看跌格局。 关键技术数据要点...
06-23 09:44
Here's How Much You Would Have Made Owning DexCom Stock In The Last 20 Years
DexCom (NASDAQ:DXCM) has outperformed the market over the past 20 years by 7.99% on an annualized basis producing an average annual return of 17.38%. Currently, DexCom has a market capitalization of $28.26 billion. Buying $100 In DXCM: If an investor had bought $100 of DXCM stock 20 years ago, it wo...
06-18 22:15
美股大行评级 | 大摩再上调希捷科技和西部数据目标价；多家大行首予Lincoln买入评级
今日重点评级关注：HC Wainwright & Co.：维持Elicio Therapeutics"买入"评级，目标价从17美元升至23美元；Leerink Partners：维持SAB Biotherapeutics"跑赢大市"评级，目标价从7美元升至12美元
06-16 11:34
Dexcom Scores Pediatric Expansion For OTC Stelo Glucose Monitor
The U.S. Food and Drug Administration (FDA) on Friday cleared Dexcom Inc.‘s (NASDAQ:DXCM) Stelo Glucose Biosensor System for over-the-counter use in children ages 2 and older who do not use insulin, expanding access to continuous glucose monitoring for younger patients. The FDA previously cleared St...
06-16 01:02
Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $88
Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $75 to $88.
06-15 21:12
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology June 15 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ferrari, Hawkeye 360 and Micron Technology, on Monday. HIGHLIGHTS * Ferrari RACE.N : Morgan Stanley ra
06-15 15:49
为何你应在投资组合中保留德康医疗公司股票
德康公司（DXCM）凭借连续血糖监测（CGM）市场潜力，未来几个季度有望增长，但面临竞争风险。其Zacks评级为#3（持有），今年迄今股价涨8.2%，同期行业跌...
06-15 15:19
DexCom's OTC CGM Stelo gains pediatric approval
The US FDA has approved DexCom's (DXCM) over-the-counter continuous glucose monitor Stelo for use in children two years and older. The indication is for children who receive oral medication for diabet...
06-13 04:20
